Primary plasma cell leukemia in the era of novel agents for myeloma – a multicenter retrospective analysis of outcome
Primary plasma cell leukemia (PPCL) is a rare aggressive form of multiple myeloma (MM), currently arbitrarily defined as the presence of ≥2 × 109/L or 20% clonal plasma cells in the peripheral blood. (Source: Leukemia Research)
Source: Leukemia Research - February 22, 2018 Category: Hematology Authors: Chezi Ganzel, Ory Rouvio, Irit Avivi, Hila Magen, Osnat Jarchowsky, Katrin Herzog, Yossi Cohen, Tamar Tadmor, Netanel A. Horwitz, Merav Leiba, Arnon Nagler, Yael Cohen, Shlomo Bulvik, Aaron Polliack, Jacob M. Rowe, Moshe E. Gatt, on behalf of the Israeli Tags: Research paper Source Type: research
Primary plasma cell leukemia in the era of novel agents for myeloma – a multicenter retrospective analysis of outcome
(Source: Leukemia Research)
Source: Leukemia Research - February 22, 2018 Category: Hematology Authors: Chezi Ganzel, Ory Rouvio, Irit Avivi, Hila Magen, Osnat Jarchowsky, Katrin Herzog, Yossi Cohen, Tamar Tadmor, Netanel Horwitz, Merav Leiba, Arnon Nagler, Yael Cohen, Shlomo Bulvik, Aaron Polliack, Jacob M Rowe, Moshe E Gatt, on behalf of the Israeli Multi Tags: Research paper Source Type: research
Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study
(Source: Leukemia Research)
Source: Leukemia Research - February 20, 2018 Category: Hematology Authors: Devendra Hiwase, Peter Tan, James D ’Rozario, John Taper, Anthony Powell, Ian Irving, Matthew Wright, Susan Branford, David T. Yeung, Luke Anderson, Othon Gervasio, Carly Levetan, Will Roberts, Ann Solterbeck, Robert Traficante, Timothy Hughes Tags: Research paper Source Type: research
AML refractory to primary induction with Ida-FLAG has a poor clinical outcome
For over four decades, standard therapy for acute myeloid leukemia (AML) has been the combination of three days of an anthracycline and seven days of cytarabine ( “3 + 7”) [1]. This combination of agents produces complete remission (CR) in approximately 35% to 95% of patients, depending on cytogenetic risk group [2]. Those who do not achieve remission with this regimen can often achieve CR with an intensive reinduction regimen. For example, in patient s who do not achieve CR with “3 + 7”, reinduction with mitoxantrone, etoposide and high dose cytarabine (NOVE-HiDAC) produces an overall response rate of 53% ...
Source: Leukemia Research - February 19, 2018 Category: Hematology Authors: Simon Kavanagh, Emily Heath, Rose Hurren, Marcela Gronda, Samir H. Barghout, Sanduni U. Liyanage, Thirushi P. Siriwardena, Jaime Claudio, Tong Zhang, Mahadeo Sukhai, Tracy L. Stockley, Suzanne Kamel-Reid, Amr Rostom, Andrzej Lutynski, Dina Khalaf, Anna Ry Tags: Research paper Source Type: research
The Impact of the Neutrophil:Lymphocyte Ratio in Response and Survival of Patients with De Novo Diffuse Large B-Cell Lymphoma
(Source: Leukemia Research)
Source: Leukemia Research - February 19, 2018 Category: Hematology Authors: Brady E. Beltr án, Sally Paredes, Esther Cotrina, Eduardo M. Sotomayor, Jorge J. Castillo Tags: Research paper Source Type: research
AML refractory to primary induction with Ida-FLAG has a poor clinical outcome
(Source: Leukemia Research)
Source: Leukemia Research - February 19, 2018 Category: Hematology Authors: Simon Kavanagh, Emily Heath, Rose Hurren, Marcela Gronda, Samir H. Barghout, Sanduni U. Liyanage, Thirushi P. Siriwardena, Jaime Claudio, Tong Zhang, Mahadeo Sukhai, Tracy L. Stockley, Suzanne Kamel-Reid, Amr Rostom, Andrzej Lutynski, Dina Khalaf, Anna Ry Tags: Research paper Source Type: research
Editorial Board
(Source: Leukemia Research)
Source: Leukemia Research - February 17, 2018 Category: Hematology Source Type: research
Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms
Persons with myeloproliferative neoplasms (MPNs) have been well-served by translational research over the past two decades, and in the instance of chronic myeloid leukemia (CML), for the past half-century. The recent publication of the long-term results of imatinib therapy with a median follow-up of 11 years, confirms the safety and efficacy of this first-generation tyrosine kinase-inhibitor (TKI) [1,2]. Clinical progress for other subtypes of MPNs has been more limited but there have been therapy advances for certain other MPNs [3]. (Source: Leukemia Research)
Source: Leukemia Research - February 15, 2018 Category: Hematology Authors: Tariq I. Mughal, Jason Gotlib, Ruben Mesa, Steffen Koschmieder, H. Jean Khoury, Jorge E. Cortes, Tiziano Barbui, R üdiger Hehlmann, Michael Mauro, Susanne Saussele, Jerald P. Radich, Richard A. Van Etten, Giuseppe Saglio, Srdnan Verstovek, Robert Peter G Source Type: research
The Importance of Meaningful Activity in People Living with Acute Myeloid Leukemia
(Source: Leukemia Research)
Source: Leukemia Research - February 15, 2018 Category: Hematology Authors: Amy L. Deckert, Galina Gheihman, Rinat Nissim, Cynthia Chung, Aaron Schimmer, Camilla Zimmermann, Gary Rodin Tags: Research paper Source Type: research
Helios Expression in Regulatory T cells Promotes Immunosuppression, Angiogenesis and the growth of leukemia cells in Pediatric Acute Lymphoblastic Leukemia
(Source: Leukemia Research)
Source: Leukemia Research - February 15, 2018 Category: Hematology Authors: Xue Li, Dong Li, Xiaoyang Huang, Panpan Zhou, Qing Shi, Bing Zhang, Xiuli Ju Tags: Research paper Source Type: research
Recent advances in the genomics and therapy of BCR/ABL1-positive and −negative chronic myeloproliferative neoplasms
(Source: Leukemia Research)
Source: Leukemia Research - February 15, 2018 Category: Hematology Authors: Tariq I. Mughal, Jason Gotlib, Ruben Mesa, Steffen Koschmieder, HJean Khoury, Jorge E. Cortes, Tiziano Barbui, R üdiger Hehlmann, Michael Mauro, Susanne Saussele, Jerald P. Radich, Richard A. Van Etten, Giuseppe Saglio, Srdnan Verstovek, Robert Peter Gal Source Type: research
Widespread use of measurable residual disease in acute myeloid leukemia practice
(Source: Leukemia Research)
Source: Leukemia Research - February 12, 2018 Category: Hematology Authors: Zachary D. Epstein-Peterson, Sean M. Devlin, Eytan M. Stein, Elihu Estey, Martin S. Tallman Tags: Research paper Source Type: research
Iron Overload in Lower International Prognostic Scoring System Risk Patients with Myelodysplastic Syndrome Receiving Red Blood Cell Transfusions: Relation to Infections and Possible Benefit of Iron Chelation Therapy
(Source: Leukemia Research)
Source: Leukemia Research - February 10, 2018 Category: Hematology Authors: Colleen A.C. Wong, Shannon A.Y. Wong, Heather A. Leitch Tags: Research paper Source Type: research
Interpretation of clinical endpoints in trials of acute myeloid leukemia
Although a few new drugs have been approved for acute myeloid leukemia (AML) based on improved survival vs standard therapy in the past 2 decades, the therapeutic landscape is currently poised to expand, with several new agents anticipated to be approved by the US Food and Drug Administration (FDA) in 2017 [1]. Midostaurin, a multitargeted fms-like tyrosine kinase 3 inhibitor, was approved by the FDA in April 2017 [2]. Enasidenib, an isocitrate dehydrogenase 2 –targeted inhibitor; CPX-351, a liposomal daunorubicin/cytarabine combination; and gemtuzumab ozogamicin, a CD33-directed antibody-drug conjugate, were FDA approve...
Source: Leukemia Research - February 7, 2018 Category: Hematology Authors: Bruno C. Medeiros Source Type: research
Targeting histone demethylases KDM5A and KDM5B in AML cancer cells: A comparative view
Chromatin organization is a major regulator of cellular processes including DNA replication, transcription, repair and recombination. The organization is controlled by histone modifications such as acetylation, methylation, phosphorylation, sumoylation and ubiquitylation [1 –3]. Among different histone modifications, methylation plays a key role in regulation of gene expression [1,4]. Histones can be methylated on lysine residues in the form of mono, di- or tri- methylation [5]. The histone acceptor (H3 vs H4), the site of lysine residue and the location of the histo ne (coding vs non-coding regions) determines whether m...
Source: Leukemia Research - February 7, 2018 Category: Hematology Authors: Gelareh Shokri, Shaghayegh Doudi, Mehrnoosh Fathi-Roudsari, Fatemeh Kouhkan, Mohammad-Hossein Sanati Tags: Research paper Source Type: research
